Terry Chrisomalis | TalkMarkets | Page 22
Pharma/Biotech Analyst
I am a graduate of Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to more

All Contributions

Latest Posts
337 to 352 of 353 Posts
<<< 1 ... 20 21 22 23 >>>
Why I'm Still Long Rxi Pharmaceuticals After Recent Developments
Rxi Pharmaceuticals provides a huge opportunity with impending phase 2 catalyst
FDA Approves Mannkind’s Afrezza, A Better Case For Patients With Diabetes
FDA approval for Afrezza was a major hurdle for Mannkind
Vertex Pharmaceuticals Creates Combo Magic For Cystic Fibrosis Patients
Vertex soars 40% on its combination drug for Cystic Fibrosis.
Isis Pharmaceuticals Shows Positive Results In Patients With Type 2 Diabetes
Isis Pharmaceuticals leads the way in diabetes utilizing RNA antisense technology
Orexigen Gets An Early Morning Surprise With FDA Delay For Contrave
The FDA issued a delay for Orexigen's (OREX) obesity drug Contrave, The stock has now fallen by more than 15% in pre-market trading, creating an investment opportunity for patient investors.
Achillion Surges As FDA Releases Hepatitis C Clinical Hold On Sovaprevir
Achillion surges 52% in one day due to the news of the FDA releasing clinical hold.
Merck Felt Lonely In The Hepatitis C Space, Acquired Idenix Pharmaceuticals
Today Merck paid $3.8 billion dollars to acquire Idenix Pharmaceuticals (IDIX) or $24.50 per share. Why would Merck want to acquire Idenix Pharmaceuticals if Gilead's Sovalid is already in the race and gaining a huge chunk of the Hepatitis C market? It had a good reason...
Rxi Pharmaceuticals Jefferies Presentation Gives Insight For Future
Rxi Pharmaceutical's Presentation Offers New Insights Into Trials. Investors should take notice of this company, as it offers a chance for patients to get treatments for unmet medical needs.
Clovis Oncology Slides Despite Positive Lung Cancer Data Presented At ASCO 2014
Clovis Oncology released impressive results showing that the cancer in 90% of test patients taking its CO-1686 did not progress further or regressed. Yet CLVS is currently tumbling by 13%. Why? Clovis failed to disclose that it also caused in increase in diabetes. AstraZeneca's ompound does not.
OncoSec Impresses With Phase 2 Melanoma Results At ASCO 2014
OncoSec Shows Positive Phase 2 Interim Results in Advanced Melanoma at ASCO 2014 creating an exciting investment opportunity for both short term traders and long term buyers.
Intercept Pharmaceuticals Has More Good News For Investors
Intercept may climb back up once again.
Valeant Won't Let Go Of Allergan, Raises Bid For The Company
Valeant Pharmaceuticals wants Allergan because of its enormous value.
Sangamo's Technology Can Possibly Advance New Treatments For Patients With HIV
Sangamo has the ability to improve HIV patient's lives with a new form of treatment
OncoSec Medical: The Game Changer In The Biotech Industry
Oncosec uses electroporation to treat cancers with immunotherapy.
Going Long On Inovio Ahead Of Phase 2 Cervical Dysplasia Data Readout
Inovio's Phase 2 Catalyst may prove to help investors get a boost in share price and may change the face of immunotherapy forever
Taking A Look At Rxi Pharmaceuticals Before Hypertrophic Scar Phase 2 Results
Rxi Pharmaceuticals stands to impress with anti-scarring results
337 to 352 of 353 Posts
<<< 1 ... 20 21 22 23 >>>